Literature DB >> 51100

Interferon-directed inhibition of chronic murine leukemia virus production in cell cultures: lack of effect on intracellular viral markers.

R M Friedman, E H Chang, J M Ramseur, M W Myers.   

Abstract

Extracellular murine leukemia virus (MLV) reverse transcriptase activity was decreased by interferon treatment in four interferon-sensitive mouse cell lines which were chronic MLV producers. In three cell lines which were relatively insensitive to interferon, extracellular enzyme activity remained unchanged by interferon treatment. The concentrations of interferon used had no effect on DNA synthesis or cell replication of AKR,C+ cells which were chronic producers of AKR-MLV. In AKR,C+ cultures interferon treatment also had no effect on the level of intracellular viral reverse transcriptase activity in spite of an inhibition of extracellular enzyme activity. Treatment of AKRC+ cultures with interferon for 9 days inhibited extracellular viral reverse transcriptase levels throughout the period of treatment; however, the intracellular enzyme activity remained unchanged, and concentrations of viral p30 (gs) antigen were increased in the interferon-treated cells. When the cells were washed to remove interferon, however, virus production rapidly rose and intracellular p30 antigen fell to the levels of untreated AKR,C+ cells. These and previously reported results suggested that in interferon-treated AKR,C+ cells virus production is inhibited at a late step in the MLV replication cycle, either directly or through the inhibition of the production of a protein required for virus assembly.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 51100      PMCID: PMC354704     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  15 in total

1.  Translation of RNA by L cell extracts: Effect of interferon.

Authors:  R M. Friedman; R M. Esteban; D H. Metz; D R. Tovell; I M. Kerr; R Williamson
Journal:  FEBS Lett       Date:  1972-08-15       Impact factor: 4.124

2.  Interferon inhibition of autogenously induced virions (C particles) in synchronized L-929 cell cultures.

Authors:  M V O'Shaughnessy; K B Easterbrook; S H Lee; L J Katz; K R Rozee
Journal:  J Natl Cancer Inst       Date:  1974-12       Impact factor: 13.506

3.  Nucleic acid and proteins isolated from a strain of murine sarcoma virus (MSV-O).

Authors:  A E Horvath; R M Friedman
Journal:  Proc Soc Exp Biol Med       Date:  1971-07

4.  Inhibition of murine leukemia virus production in chronically infected AKR cells: a novel effect of interferon.

Authors:  R M Friedman; J M Ramseur
Journal:  Proc Natl Acad Sci U S A       Date:  1974-09       Impact factor: 11.205

Review 5.  RNA-directed DNA polymerase--properties and functions in oncogenic RNA viruses and cells.

Authors:  M Green; G F Gerard
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1974

6.  Purification of mouse interferon by affinity chromatography on anti-interferon globulin-sepharose.

Authors:  C A Ogburn; K Berg; K Paucker
Journal:  J Immunol       Date:  1973-10       Impact factor: 5.422

7.  Inhibition of arbovirus protein synthesis by interferon.

Authors:  R M Friedman
Journal:  J Virol       Date:  1968-10       Impact factor: 5.103

8.  Concerning the mechanism of action of interferon.

Authors:  W K Joklik; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1966-08       Impact factor: 11.205

9.  Xenotropic viruses: murine leukemia viruses associated with NIH Swiss, NZB, and other mouse strains.

Authors:  J A Levy
Journal:  Science       Date:  1973-12-14       Impact factor: 47.728

10.  Interferon and transcription of early virus-specific RNA in cells infected with simian virus 40.

Authors:  M N Oxman; M J Levin
Journal:  Proc Natl Acad Sci U S A       Date:  1971-02       Impact factor: 11.205

View more
  25 in total

1.  Evaluation of the antiviral effect of new compounds by using cellular cultures.

Authors:  F Dianzani; G Antonelli
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

Review 2.  Mechanisms of persistent infections by cytopathic viruses in tissue culture. Brief review.

Authors:  R M Friedman; J M Ramseur
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

3.  Interferon treatment of NZB mice: accelerated progression of autoimmune disease.

Authors:  H Heremans; A Billiau; A Colombatti; J Hilgers; P de Somer
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

4.  Specificity of interferon action in protein synthesis.

Authors:  P M Yau; T Godefroy-Colburn; C H Birge; T V Ramabhadran; R E Thach
Journal:  J Virol       Date:  1978-09       Impact factor: 5.103

5.  Studies on in vitro interferon induction capacity and interferon sensitivity of simian foamy viruses.

Authors:  A Rhodes-Feuillette; F Saal; J Lasneret; M Santillana-Hayat; J Peries
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

6.  Physical, morphological, and biochemical alterations in the membrane of AKR mouse cells after interferon treatment.

Authors:  E H Chang; F T Jay; R M Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

Review 7.  The interferon system as a basis for antiviral therapy or prophylaxis.

Authors:  A Billiau
Journal:  Antiviral Res       Date:  1985       Impact factor: 5.970

8.  Characterization of intracellular viral RNA in interferon-treated cells chronically infected with murine leukemia virus.

Authors:  S Salzberg; M Bakhanashvili; S Bari; I Berman; M Aboud
Journal:  J Virol       Date:  1980-09       Impact factor: 5.103

9.  The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice.

Authors:  C Adam; Y Thoua; P Ronco; P Verroust; M Tovey; L Morel-Maroger
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

10.  Virus-specific RNA synthesis in interferon-treated mouse cells productively infected with Moloney murine leukemia virus.

Authors:  H Fan; P MacIsaac
Journal:  J Virol       Date:  1978-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.